Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin and Tea Polyphenols for ESCC Prevention
NCT01496521Phase 3Unknown
- Sponsor
- Beijing Friendship Hospital
- Start
- Jan 2012
- Primary completion
- Jun 2012
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aspirin in Esophageal Squamous Cell Carcinoma (ESCC) (3 arms), sponsored by Beijing Friendship Hospital. Primary endpoint: Occurrence of high grade dysplasia and invasive Esophageal Squamous Cell Carcinoma at 6 months. Status: unknown.
02
Drugs
aspirin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT01496521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01496521.